NDA 213556, held by Shanghai Desana Bio-Pharmaceuticals Co Ltd. Dolutegravir; Lamivudine; Tenofovir Disoproxil Fumarate.
As of Nov 14, 2026, NDA 213556 (Dolutegravir, Lamivudine And Tenofovir Disoproxil Fumarate), held by Shanghai Desana Bio-Pharmaceuticals Co Ltd, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2020 | Original applicationNew combination · Standard review | Tentative approval |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dolutegravir, Lamivudine And Tenofovir Disoproxil Fumarate50MG; 300MG; 300MG · tablet;oral | Dolutegravir; Lamivudine; Tenofovir Disoproxil Fumarate | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
